A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
A 15-year follow-up from the SWOG S0016 trial suggests that CHOP-based chemoimmunotherapy can achieve durable remission—and potential cure—in a substantial subset of patients with advanced-stage follicular lymphoma.
A 15-year follow-up from the SWOG S0016 trial suggests that CHOP-based chemoimmunotherapy can achieve durable remission—and potential cure—in a substantial subset of patients with advanced-stage follicular lymphoma.
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
A recent retrospective analysis of real-world data published in Clinical Lymphoma, Myeloma, and Leukemia, evaluated treatment outcomes in patients with follicular lymphoma (FL) grades 1-3A receiving frontline bendamustine plus rituximab (BR)...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
